Business Context and Reporting Period
Company: iBio, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2014
Business Overview: iBio is a biotechnology company focused on commercializing proprietary plant-based protein expression technologies (iBioLaunch and iBioModulator platforms) for vaccines and therapeutic proteins. The company operates in one segment and maintains a subsidiary in Brazil (iBio Brazil) to manage local business activities.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2014 | Six Months Ended Dec 31, 2013 |
|---|---|---|
| Revenues | $1,186,000 | $0 |
| Net Loss | $(3,063,000) | $(1,245,000) |
| Operating Loss | $(3,082,000) | $(1,395,000) |
| Cash and Cash Equivalents (End of Period) | $7,363,000 | $5,678,000 |
| Net Cash Used in Operating Activities | $(2,193,000) | $(2,205,000) |
| Net Cash Provided by Financing Activities | $6,079,000 | $3,551,000 |
| Total Assets | $11,042,000 | $6,494,000 (June 30, 2014) |
| Accumulated Deficit | $(44,265,000) | $(41,202,000) (June 30, 2014) |
Debt and Liquidity: The company reported no long-term debt. Total current liabilities were $1,475,000 as of December 31, 2014. The company maintains a $10 million stock purchase agreement with Aspire Capital Fund, LLC, which has been utilized to raise capital.
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $1,186,000 in revenue for the six months ended December 31, 2014, compared to zero in the prior year. This revenue stems from technology services provided to FioCruz (Brazil) for yellow fever vaccine development, following the amendment of a collaboration agreement in June 2014.
- Expense Increases: Research and development (R&D) expenses increased to $1.9 million (from $96,000 reported in 2013, which included a $1.04 million credit from a prior settlement). General and administrative (G&A) expenses rose to $2.35 million (from $1.3 million in 2013, which included a $700,000 credit). The increases are primarily due to resumed R&D activities and higher legal fees.
- Cash Position: Cash balances increased from $3.59 million (June 30, 2014) to $7.36 million (December 31, 2014), driven by $6.08 million in financing proceeds from the sale of common stock and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The filing explicitly states that the company's history of significant losses, negative cash flows, and accumulated deficit of $44.3 million raise substantial doubt about its ability to continue as a going concern. Management expects current cash resources ($7.4 million) plus funds from the Aspire Capital agreement to support operations through December 31, 2015.
Capital Strategy: The company relies on the Aspire Capital purchase agreement (up to $10 million total) and potential future equity offerings. As of February 23, 2015, $7.2 million had been raised under this agreement. The company has a $100 million shelf registration (Form S-3) effective as of December 2, 2014, but no securities have been issued under it yet.
Legal Proceedings:
- PlantForm Corporation: iBio filed a complaint in Delaware Court of Chancery alleging interference with contracts and misappropriation of intellectual property.
- Class Action: A putative securities class action was filed in October 2014 alleging violations of federal securities laws. The outcome is uncertain, and no loss estimate can be determined.
Unusual Items: The prior year's financials were significantly impacted by a Settlement Agreement with Fraunhofer (completed in September 2013), which resulted in the reversal of approximately $1.9 million in expenses. The current period does not include similar one-time credits.
Investor Verification Checklist
- Cash Runway: Verify if the $7.4 million cash balance and the remaining $2.8 million available under the Aspire Capital agreement are sufficient to fund operations beyond December 2015 without further dilution.
- Revenue Sustainability: Confirm the status of the FioCruz collaboration and whether the $1.2 million revenue recognized is recurring or a one-time reconciliation of prior services.
- Legal Exposure: Monitor the progress of the PlantForm lawsuit and the securities class action, as adverse outcomes could result in significant monetary damages or injunctions.
- Dilution Risk: Assess the impact of the Aspire Capital agreement and potential future equity issuances on existing shareholders, given the "Floor Price" mechanism ($0.44) and the company's reliance on equity financing.
- Contractual Commitments: Review the $3 million commitment to engage Fraunhofer for R&D work by December 31, 2015, of which $2 million has been performed as of the reporting date.